Pfizer expects $54 billion in 2022 sales on Covid vaccine and treatment pill

  • Pfizer expects to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid.
  • But the drugmaker posted mixed fourth-quarter results, beating on earnings but missing on revenue.
  • Pfizer forecasts $98 billion to $102 billion in sales for 2022, and adjusted earnings per share of $6.35 to $6.55.
  • On an unadjusted basis, fourth-quarter profit soared more than fourfold to $3.39 billion.

 

www.cnbc.com/2022/02/08/covid-pfizer-pfe-earnings-q4-2021.html

We are primarily funded by readers. Please subscribe and donate to support us!
Views:

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.